[Effect of benidipine on plasma level of calcitonin gene-related peptide in essential hypertension].

Abstract

OBJECTIVE:

To explore the effect of benidipine, a calcium channel blocker on the plasma levels of calcitonin gene-related peptide (CGRP) in patients with essential hypertension.

METHODS:

58 outpatients with essential hypertension were treated with benidipine 4-8 mg/day for 8 weeks. 38 matched healthy people were taken as controls. The plasma levels of CGRP were measured in all patients before and after treatment and in controls.

RESULTS:

The plasma levels of CGRP in hypertensive patients were significantly lower than those in controls (minimal value: 1.28 vs 39.95 ng/L; maximal value: 43.72 vs 155.59 ng/L; P <0.001). In hypertensive patients, treatment with benidipine for 2 weeks markedly decreased systolic pressure and diastolic pressure and its depressor effect was maintained during the study (P <0.05). At 8 week after treatment, the plasma levels of CGRP in hypertensive patients were significantly increased compared with those before treatment (minimal value: 2.84 vs 1.28 ng/L; maximal value: 123.99 vs 43.72 ng/L; P <0.001).

CONCLUSION:

Benidipine, a calcium channel blocker significantly decreases blood pressure concomitantly with an increase in the plasma levels of CGRP in the patients with essential hypertension.

• Authors: Wen-ying Jin, Wei Sun, Yong-zhen Zhang, Hai-yan Li, Ming-zhe Chen, Jing-Xuan Guo
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 43 Issue 10 Pg. 747-9 (Oct 2004) ISSN: 0578-1426 [Print] China
• PMID: 15631826 (Publication Type: Journal Article)

Chemical References

• Calcium Channel Blockers
• Dihydropyridines
• benidipine
• Calcitonin Gene-Related Peptide

Topics

• Adult
• Aged
• Calcitonin Gene-Related Peptide (blood)
• Calcium Channel Blockers (pharmacology, therapeutic use)
• Dihydropyridines (pharmacology, therapeutic use)
• Female
• Humans
• Hypertension (blood, drug therapy)
• Male
• Middle Aged